Nova Eye Medical Limited (EYE) Q4 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Okay, good morning everybody and thanks again for joining us. My name is Mark Flynn, Investor Relations at Novi Medical. Today we're covering the June 26th quarterly report which we lodged last week with the ASX and also we'll provide some outlook on FY27. Presenting as always today is Tom Sperling, our Managing Director. Again, Q&A available if you look inside Zoom. Q&A function. We'll look to get to as many questions as possible. Also, we can follow up post the webinar, but I will ask a number of questions. So please place them in the Q&A function within Zoom. As we can see from the recent results, Tom's led the company through a wonderful four consecutive years of sales growth, above 25%. And our FY26 closed at just below US$24 million, up 26%. And the second half delivered the company's first positive EBITDA as guided by Tom and the team. So Tom will take you through these results, what drove it, and also it provides an FY27 guidance. So over to you, Tom. Thanks, Mark. I'm very pleased, again, to be speaking and talking to our company. It's another record attendance, and having a lot of people interested in our company, another record attendance webinar, having a lot of people interested in our company is very, I'll just say heartwarming, because it is. Now you see our opening slide. Just leave it up there. Sorry, Mark. Just back, back, back. Our opening slide, I just want to say regular viewers will note that that's quite a change in our slide formatting and that's intentional. We've hit some major milestones in this last half and we are different. We are combining profitability with sales growth just as we promised. We promised it and we've delivered it. It's a big thing today. Thanks, Mark. Let's just not forget glaucoma. The second leading cause of blindness ...